Trial NCT02413827

View at ClinicalTrials.gov 
Org. Study IDs: CDX1127-03

Last trial update was posted on 2017-04-07

MeSH Interventions

Antibodies, Monoclonal Ipilimumab Poly ICLC

MeSH Conditions

Melanoma

Other Conditions

Unresectable Stage III or Stage IV Melanoma

Stopping Reasons

Feasibility concerns due to changes in standard of care

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID